A5081777867- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Bladder and Urothelial Cancer Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Urologic and reproductive health conditions
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Renal and related cancers
- Economic and Financial Impacts of Cancer
- Surgical Simulation and Training
- Global Cancer Incidence and Screening
- Pediatric Urology and Nephrology Studies
- Statistical Methods in Clinical Trials
- Advanced Radiotherapy Techniques
- Multiple and Secondary Primary Cancers
- Urological Disorders and Treatments
- Cardiac, Anesthesia and Surgical Outcomes
- MRI in cancer diagnosis
- Ureteral procedures and complications
- Cancer Diagnosis and Treatment
- Nutritional Studies and Diet
- Cancer Immunotherapy and Biomarkers
The University of Texas MD Anderson Cancer Center
2016-2025
The University of Texas at Austin
2024
Mayo Clinic Hospital
2024
Yale New Haven Health System
2024
National Hospital
2022
GTx (United States)
2020
The Ohio State University
2019
Fondazione Vincenzo Pansadoro
2018
University of Illinois Chicago
2016
University of Chicago
2016
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management localized disease, post-treatment monitoring, treatment recurrence advanced disease. sections included in this article focus metastatic castration-sensitive nonmetastatic castration-resistant cancer (CRPC), CRPC (mCRPC). Androgen deprivation therapy (ADT) intensification is strongly recommended cancer. For CRPC, ADT...
There is growing interest in the role of local therapies, including external beam radiotherapy (RT), for men with metastatic prostate cancer (mPCa). We used National Cancer Database (NCDB) to evaluate overall survival (OS) mPCa treated androgen deprivation (ADT) and without RT.The NCDB was queried newly diagnosed mPCa, all ADT, complete datasets RT, surgery, prostate-specific antigen (PSA) level, Gleason score, Charlson-Deyo comorbidity score. OS analyzed using Kaplan-Meier method, log-rank...
The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic disease after exhaustion local options as well those hormone-sensitive prostate cancer. Please refer II discussion management castration-resistant disease.The systematic review utilized inform this guideline was conducted by an independent...
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis include management options localized, regional, recurrent, metastatic disease. Panel meets annually to reevaluate update their recommendations based on new clinical data input from within Member Institutions external entities. These Insights summarizes much of the panel's discussions 4.2022 1.2023 updates guidelines regarding systemic therapy cancer.
Despite evidence demonstrating an overall survival benefit with up-front hormone therapy in addition to established synergy between and radiation, the of metastasis-directed (MDT) for oligometastatic prostate cancer, date, has not been evaluated a randomized clinical trial.
The NCCN Guidelines for Prostate Cancer include recommendations staging and risk assessment after a prostate cancer diagnosis the care of patients with localized, regional, recurrent, metastatic disease. These Insights summarize panel's discussions 2024 update to guidelines regard initial stratification, management very-low-risk disease, treatment nonmetastatic recurrence.
Radiohybrid (rh)
Low–tumor mutational burden prostate tumors express neoantigens that elicit T cell responses associated with favorable clinical outcomes to ipilimumab.
You have accessJournal of UrologyAUA Guideline1 Jan 2021Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II William T. Lowrance,*, Rodney H. Breau, Roger Chou, Brian F. Chapin, Tony Crispino, Robert Dreicer, David Jarrard, Adam S. Kibel, Todd M. Morgan, Alicia K. Morgans, Oh, Matthew J. Resnick, Anthony L. Zietman, and Michael Cookson Lowrance,*William Lowrance,* More articles by this author , BreauRodney Breau ChouRoger Chou ChapinBrian Chapin CrispinoTony Crispino DreicerRobert...
SPOTLIGHT (NCT04186845) evaluated diagnostic performance and safety of radiohybrid
The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring patients who have experienced a recurrence following prior treatment with curative intent. This is Part I of three-part series focusing decision-making at the time suspected biochemical (BCR) after radical prostatectomy (RP). Please refer II discussion delivery non-metastatic BCR RP III evaluation management radiotherapy (RT)...
The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring patients who have experienced a recurrence following prior treatment with curative intent. This is Part III of three-part series focusing evaluation management suspected non-metastatic after radiotherapy (RT) focal therapy, regional recurrence, molecular imaging metastatic future directions. Please refer I discussion...
The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring patients who have experienced a recurrence following prior treatment with curative intent. This is Part II of three-part series focusing delivery non-metastatic biochemical (BCR) after primary radical prostatectomy (RP). Please refer I discussion decision-making III evaluation management radiotherapy (RT) focal therapy,...
Among men with localized high-risk prostate cancer (PCa), patients who meet very (VHR) criteria have been shown to experience worse outcomes after radical prostatectomy (RP) in a previous study. Variations of VHR suggested be prognostic other single-center cohorts, but multicenter validating not described. This study was designed validate for identifying which PCa are at greatest risk progression.Patients undergoing RP (2005-2015) 3 tertiary centers were pooled. The compared the those did...
No AccessJournal of UrologyAdult Urology1 Oct 2011Can a Durable Disease-Free Survival be Achieved With Surgical Resection in Patients Pathological Node Positive Renal Cell Carcinoma? Scott E. Delacroix, Brian F. Chapin, Jaclyn J. Chen, Graciela M. Nogueras-Gonzalez, Pheroze Tamboli, Surena Matin, and Christopher G. Wood DelacroixScott Delacroix Department Urology, The University Texas M.D. Anderson Cancer Center, Houston, , ChapinBrian Chapin ChenJaclyn Chen Nogueras-GonzalezGraciela...
Objective To compare radical prostatectomy (RP) vs radiotherapy (RT) with androgen‐deprivation therapy (ADT) in the setting of patients high‐risk and very (VHR) prostate cancer who were deemed eligible for either made a treatment choice after consultation multidisciplinary clinic (MDPCC), to MDPCC patients’ outcomes matched Surveillance, Epidemiology End Results (SEER) cohort. Patients methods Prospectively collected, retrospective study comparing underwent RP (231 patients) RT+ADT (73) from...